Impact of Early Intrapatient Variability of Tacrolimus Concentrations on the Risk of Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide

• Main Authors: Daniel N. Marco (Author), María Queralt Salas (Author), Gonzalo Gutiérrez-García (Author), Inés Monge (Author), Gisela Riu (Author), Esther Carcelero (Author), Joan Ramón Roma (Author), Noemí Llobet (Author), Jordi Arcarons (Author), María Suárez-Lledó (Author), Nuria Martínez (Author), Alexandra Pedraza (Author), Ariadna Domenech (Author), Laura Rosiñol (Author), Francesc Fernández-Avilés (Author), Álvaro Urbano-Ispízua (Author), Montserrat Rovira (Author), Mercè Brunet (Author), Carmen Martínez (Author)
• Format: Book
• Published: MDPI AG, 2022-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Tacrolimus (Tac) is a pivotal immunosuppressant agent used to prevent graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (alloHSCT). Tac is characterized by a narrow therapeutic window and a high inter-patient and intra-patient pharmacokinetic variability (IPV). Although hig...